Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach.

Consensus virtual screening models were generated and validated utilizing a set of known human epidermal growth factor receptor-2 (HER2) inhibitors and modeled HER2 active and inactive state structures. The virtual screening models were successfully employed to discover a set of structurally diverse compounds with growth inhibitory activity against HER2-overexpressing SKBR3 breast cancer cell line. A search of a 3D database containing 350000 small-molecules using the consensus models retrieved 531 potential hits. Of the 531 hits, 57 were selected for testing in SKBR3 cells on the basis of structural novelty and desirable drug-like properties. Seven compounds inhibited growth of SKBR3 cells with IC50 values <10 microM. These lead compounds have desirable physicochemical properties and are excellent candidates for further optimization.

[1]  Magdalena Bacilieri,et al.  Combining ligand-based and structure-based drug design in the virtual screening arena , 2007, Expert opinion on drug discovery.

[2]  R. Nilakantan,et al.  6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. , 2001, Journal of medicinal chemistry.

[3]  Xiao-min Luo,et al.  Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors. , 2005, Bioorganic & medicinal chemistry.

[4]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[5]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[6]  J. Smaill,et al.  Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor. , 2001, Journal of medicinal chemistry.

[7]  Mitsuru Kajioka,et al.  Preparation of 1,2,4-triazole derivative , 1979 .

[8]  M. Sliwkowski,et al.  Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.

[9]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[10]  Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. , 2004, Bioorganic & medicinal chemistry letters.

[11]  F. Shepherd,et al.  Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  A. Wells.  EGF receptor. , 1999, The international journal of biochemistry & cell biology.

[13]  Ramaswamy Nilakantan,et al.  Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2) , 2003 .

[14]  G. Mcmahon,et al.  Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. , 1998, Journal of medicinal chemistry.

[15]  A. M. Stanley,et al.  Structure of the extracellular region of HER 2 alone and in complex with the Herceptin Fab , 2022 .

[16]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[17]  M. Poupon,et al.  Grb2‐SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel , 2007, International journal of cancer.

[18]  Gautam R. Desiraju,et al.  Virtual Screening of 4-Anilinoquinazoline Analogues as EGFR Kinase Inhibitors: Importance of Hydrogen Bonds in the Evaluation of Poses and Scoring Functions , 2005, J. Chem. Inf. Model..

[19]  M. Sliwkowski,et al.  Binding specificities and affinities of egf domains for ErbB receptors , 1999, FEBS letters.

[20]  Gabriela Chiosis,et al.  Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. , 2005, Journal of medicinal chemistry.

[21]  N. Zhang,et al.  4‐Anilino‐3‐cyanobenzo[g]quinolines as Kinase Inhibitors. , 2002 .

[22]  A Seaton,et al.  Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents. , 2000, Journal of medicinal chemistry.

[23]  A. Bridges,et al.  Chemical inhibitors of protein kinases. , 2001, Chemical reviews.

[24]  Ramaswamy Nilakantan,et al.  Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. , 2005, Journal of medicinal chemistry.

[25]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[26]  A Whitty,et al.  Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. , 1997, Journal of medicinal chemistry.

[27]  K. Lackey,et al.  Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines. , 2003, Bioorganic & medicinal chemistry letters.

[28]  A. Levitzki,et al.  Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. , 1991, Journal of medicinal chemistry.

[29]  D. Fabbro,et al.  Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases. , 2004, Mini-Reviews in Medical Chemistry.

[30]  Jeffrey Jie-Lou Liao,et al.  Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors , 2007 .

[31]  J. Fargnoli,et al.  Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. , 2005, Journal of medicinal chemistry.

[32]  J. D. de Bono,et al.  Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). , 2007, European journal of cancer.

[33]  O. H. Chan,et al.  Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. , 2000, Journal of medicinal chemistry.

[34]  L. Cantley,et al.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Aniko Simon,et al.  eHiTS: a new fast, exhaustive flexible ligand docking system. , 2007, Journal of molecular graphics & modelling.

[36]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[37]  P. Leder,et al.  A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells. , 2005, Cancer research.